Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin [clinicaltrials:NCT01074697]

Bio2RDF identifier

NCT01074697

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT01074697

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT01074697

acronym [clinicaltrials_vocabulary:acronym]

GAND-emesis

http://www.w3.org/2001/XMLSchema#string

actual enrollment [clinicaltrials_vocabulary:actual-enrollment]

246

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT01074697 arm group 51c80fb5405eb51050796a7d5ec93fba [clinicaltrials_resource:NCT01074697/arm-group/51c80fb5405eb51050796a7d5ec93fba]

NCT01074697 arm group ccc09dc3febeedba45ad36ed8e3f57c8 [clinicaltrials_resource:NCT01074697/arm-group/ccc09dc3febeedba45ad36ed8e3f57c8]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:ddbab52d9500a9988b550be010e48018

brief summary [clinicaltrials_vocabulary:brief-summary]

GAND-emesis is a multin ...... ned chemo-radiotherapy.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Efficacy of Two Antiemetic Reg ...... d Concomitant Weekly Cisplatin

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

To compare fosaprepitant dimeglumine, palonosetron, and dexamethasone with palonosetron, dexamethasone, and placebo with respect to efficacy; the proportion of subjects with no vomiting during five weeks of radiotherapy and concomitant weekly cisplatin. 35 days [clinicaltrials_resource:13169c7fcc7b4e7a27b57f5a07ce79af]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

To compare fosaprepitant dimeglumine, palonosetron, and dexamethasone with palonosetron, dexamethasone, and placebo with respect to efficacy; the proportion of subjects with no vomiting during five weeks of radiotherapy and concomitant weekly cisplatin. 35 days [clinicaltrials_resource:10c1c6d6cac9bc8f6863461901374594]

To compare fosaprepitant dimeglumine, palonosetron, and dexamethasone with palonosetron, dexamethasone, and placebo with respect to efficacy; the proportion of subjects with no vomiting during five weeks of radiotherapy and concomitant weekly cisplatin. 35 days [clinicaltrials_resource:77f0b6d8ea34dc69cfd97438ebd3f253]

To compare fosaprepitant dimeglumine, palonosetron, and dexamethasone with palonosetron, dexamethasone, and placebo with respect to efficacy; the proportion of subjects with no vomiting during five weeks of radiotherapy and concomitant weekly cisplatin. 35 days [clinicaltrials_resource:88884e07665b702214ab632004b89645]

To compare fosaprepitant dimeglumine, palonosetron, and dexamethasone with palonosetron, dexamethasone, and placebo with respect to efficacy; the proportion of subjects with no vomiting during five weeks of radiotherapy and concomitant weekly cisplatin. 35 days [clinicaltrials_resource:b93d04fcabaf099252187545fe0b7ad6]

To compare fosaprepitant dimeglumine, palonosetron, and dexamethasone with palonosetron, dexamethasone, and placebo with respect to efficacy; the proportion of subjects with no vomiting during five weeks of radiotherapy and concomitant weekly cisplatin. 35 days [clinicaltrials_resource:dd7dd52ec0b565e15da992a918e274f9]

To compare fosaprepitant dimeglumine, palonosetron, and dexamethasone with palonosetron, dexamethasone, and placebo with respect to efficacy; the proportion of subjects with no vomiting during five weeks of radiotherapy and concomitant weekly cisplatin. 35 days [clinicaltrials_resource:ecc6d11c63b912add5fc90e7182e9a3d]

To compare fosaprepitant dimeglumine, palonosetron, and dexamethasone with palonosetron, dexamethasone, and placebo with respect to efficacy; the proportion of subjects with no vomiting during five weeks of radiotherapy and concomitant weekly cisplatin. 35 days [clinicaltrials_resource:f9b68fb52442292f87e480e27d1493f4]

collaborator [clinicaltrials_vocabulary:collaborator]

Odense University Hospital [clinicaltrials_resource:2c2641499f975fdcec6c980c3ec52760]

completion date [clinicaltrials_vocabulary:completion-date]

2015-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT01074697 [clinicaltrials_resource:f55f2d0e87288af37e02c6cce6fa56b8]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2010-02-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Placebo [clinicaltrials_resource:2695a2f87b0227b484fb170463ede6b9]

Fosaprepitant dimeglumine [clinicaltrials_resource:64cd3efaa934ffac5f964f628e034c14]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Palonosetron [clinicaltrials_resource:372ff5ebc1560ce25f8bdaab022b874f]

Dexamethasone acetate [clinicaltrials_resource:3aceb7ffcdb81af25927c64a2943afbf]

Aprepitant [clinicaltrials_resource:61cb8d8764b625be6b962c21424d6aad]

Dexamethasone [clinicaltrials_resource:81150ffec96d15927ad7a74665708ef9]

Fosaprepitant [clinicaltrials_resource:8e4ccd64ec893783c0127e9e8b78c35d]

BB 1101 [clinicaltrials_resource:9455fd6ce25c7014db1539bee52b8740]

Dexamethasone 21-phosphate [clinicaltrials_resource:9aea03ec731911e4ff43f23b2ed51296]

Cisplatin [clinicaltrials_resource:b8c8989cecf98bb7fbbfc2be8c78bee6]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

No

http://www.w3.org/2001/XMLSchema#string

keyword [clinicaltrials_vocabulary:keyword]

Cisplatin

http://www.w3.org/2001/XMLSchema#string

Dexamethasone

http://www.w3.org/2001/XMLSchema#string

Prevention & control

http://www.w3.org/2001/XMLSchema#string

Radiotherapy

http://www.w3.org/2001/XMLSchema#string

Randomized Controlled Trial

http://www.w3.org/2001/XMLSchema#string

Receptors, Neurokinin-1

http://www.w3.org/2001/XMLSchema#string

Serotonin Agonists

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-04-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Odense University Hospital [clinicaltrials_resource:2c2641499f975fdcec6c980c3ec52760]

location [clinicaltrials_vocabulary:location]

RAH Cancer Centre, Royal Adelaide Hospital [clinicaltrials_resource:69ab26a99be6d9d87ad89c293d9595a0]

nct id [clinicaltrials_vocabulary:nct-id]

NCT01074697

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

2

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Multinational, Randomized, D ...... otherapy and Weekly Cisplatin.

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

GAND-emesis

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Jorn Herrstedt, MD, DMSci [clinicaltrials_resource:2987a23d68f9dbaf259f4e0ef5556dca]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

Denmark: Danish Medicines Agency [clinicaltrials_resource:15d5ac1657a93ee93019acf3129dd2cd]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2015-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:74007f2eb9edfd35f93d01c0e31ae201]

secondary id [clinicaltrials_vocabulary:secondary-id]

2009-014691-21

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

Odense University Hospital [clinicaltrials_resource:2c2641499f975fdcec6c980c3ec52760]

start date [clinicaltrials_vocabulary:start-date]

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT01074697 study design [clinicaltrials_resource:ebad60750c7523823cd4054403933470]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT01074697

verification date [clinicaltrials_vocabulary:verification-date]

2015-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT01074697

http://www.w3.org/2001/XMLSchema#string

title

Efficacy of Two Antiemetic Reg ...... d Concomitant Weekly Cisplatin

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]